Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

  1. Mok, T.S.
  2. Cheng, Y.
  3. Zhou, X.
  4. Lee, K.H.
  5. Nakagawa, K.
  6. Niho, S.
  7. Chawla, A.
  8. Rosell, R.
  9. Corral, J.
  10. Migliorino, M.R.
  11. Pluzanski, A.
  12. Noonan, K.
  13. Tang, Y.
  14. Pastel, M.
  15. Wilner, K.D.
  16. Wu, Y.-L.
Revista:
Drugs

ISSN: 1179-1950,  0012-6667

Ano de publicación: 2021

Volume: 81

Número: 2

Páxinas: 257-266

Tipo: Artigo

DOI: 10.1007/S40265-020-01441-6 GOOGLE SCHOLAR lock_openAcceso aberto editor
Fonte de datos: Scopus